Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-finding and Safety Study of an Oncolytic Polio/Rhinovirus Recombinant Against Recurrent WHO Grade IV Malignant Glioma

NCT01491893 is registered in ClinicalTrials.gov with Istari Oncology, Inc. as lead sponsor.

NCT NCT01491893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01491893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-finding and Safety Study of an Oncolytic Polio/Rhinovirus Recombinant Against Recurrent WHO Grade IV Malignant Glioma
Lead sponsor
Istari Oncology, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 25, 2012
Completion date
October 1, 2021
Enrollment
61 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gbm, glioblastoma, glioma, malignant glioma